Printer Friendly

COMPANY INFORMATION
Oncolytics Biotech Inc. 210-1167 Kensington Cres NW Calgary, AB T2N 1X7 Tel: (403) 670-7377 Fax: (403) 283-0858 Contact Name Cathy Ward Industry Biotechnology		Key Executives Bradley G. Thompson, CEO Douglas A. Ball, CFO Develops and discovers oncolytic viruses for the treatment of cancers that have not been successfully treated with conventional therapeutics.
FP ADVISOR COVERAGE Oncolytics Biotech Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/ONC Nasdaq/ONCY $2.81 $4.10 $1.41 n.a. n.a. n.a. 0.46 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 100,583 n.a. $-0.34 Sept. 30/09 81.29% 0.36% -11.24% $171,164
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 $000s $000s $000s Net income (17,550) (15,642) (14,298) Total assets 13,987 30,782 33,566 $ $ $ Earnings per share* (0.42) (0.39) (0.39) % % % Return on equity (93.82) (53.24) (38.00)   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 $000s $000s Net income (15,747) (16,804) $ $ Earnings per share (0.34) (0.41)

COMPANY NEWS

Results for 'Oncolytics Biotech Inc.' from past 30 days: No hits. (Links are to articles.)